These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 23407781)

  • 21. Behavioral arrest and a characteristic slow waveform are hallmark responses to selective 5-HT
    Contreras A; Khumnark M; Hines RM; Hines DJ
    Sci Rep; 2021 Jan; 11(1):1925. PubMed ID: 33479368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the 5-HT
    Jaster AM; Elder H; Marsh SA; de la Fuente Revenga M; Negus SS; González-Maeso J
    Psychopharmacology (Berl); 2022 Jun; 239(6):1665-1677. PubMed ID: 35233648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. G
    Liu X; Zhu H; Gao H; Tian X; Tan B; Su R
    Biochem Biophys Res Commun; 2022 Apr; 598():20-25. PubMed ID: 35149433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor.
    Halberstadt AL; Geyer MA
    Psychopharmacology (Berl); 2010 Feb; 208(2):179-89. PubMed ID: 19937319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran ("FLY") and benzodifuran ("DragonFLY") analogs.
    Halberstadt AL; Chatha M; Stratford A; Grill M; Brandt SD
    Neuropharmacology; 2019 Jan; 144():368-376. PubMed ID: 30385253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD).
    Brandt SD; Kavanagh PV; Westphal F; Stratford A; Odland AU; Klein AK; Dowling G; Dempster NM; Wallach J; Passie T; Halberstadt AL
    Drug Test Anal; 2020 Jun; 12(6):812-826. PubMed ID: 32180350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.
    Borroto-Escuela DO; Romero-Fernandez W; Narvaez M; Oflijan J; Agnati LF; Fuxe K
    Biochem Biophys Res Commun; 2014 Jan; 443(1):278-84. PubMed ID: 24309097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice.
    Smith DA; Bailey JM; Williams D; Fantegrossi WE
    J Pharmacol Exp Ther; 2014 Dec; 351(3):485-91. PubMed ID: 25271256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Hallucinogens on Unconditioned Behavior.
    Halberstadt AL; Geyer MA
    Curr Top Behav Neurosci; 2018; 36():159-199. PubMed ID: 28224459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex.
    Gresch PJ; Smith RL; Barrett RJ; Sanders-Bush E
    Neuropsychopharmacology; 2005 Sep; 30(9):1693-702. PubMed ID: 15756304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT₂A receptors, in mice.
    Fantegrossi WE; Gray BW; Bailey JM; Smith DA; Hansen M; Kristensen JL
    Psychopharmacology (Berl); 2015 Mar; 232(6):1039-47. PubMed ID: 25224567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen.
    Halberstadt AL; van der Zee JVF; Chatha M; Geyer MA; Powell SB
    Psychopharmacology (Berl); 2019 Feb; 236(2):821-830. PubMed ID: 30448990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential ontogenesis of three DOI-induced behaviors in mice.
    Darmani NA; Shaddy J; Gerdes CF
    Physiol Behav; 1996 Dec; 60(6):1495-500. PubMed ID: 8946497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis.
    Marona-Lewicka D; Thisted RA; Nichols DE
    Psychopharmacology (Berl); 2005 Jul; 180(3):427-35. PubMed ID: 15723230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
    Marek GJ; Aghajanian GK
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1373-82. PubMed ID: 8819525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of the sigma-1 receptor selective compound LS-1-137 on the DOI-induced head twitch response in mice.
    Malik M; Rangel-Barajas C; Mach RH; Luedtke RR
    Pharmacol Biochem Behav; 2016 Sep; 148():136-44. PubMed ID: 27397487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrahippocampal LSD accelerates learning and desensitizes the 5-HT(2A) receptor in the rabbit, Romano et al.
    Romano AG; Quinn JL; Li L; Dave KD; Schindler EA; Aloyo VJ; Harvey JA
    Psychopharmacology (Berl); 2010 Oct; 212(3):441-8. PubMed ID: 20827462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs.
    Klein LM; Cozzi NV; Daley PF; Brandt SD; Halberstadt AL
    Neuropharmacology; 2018 Nov; 142():231-239. PubMed ID: 29499272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.
    Halberstadt AL
    Behav Brain Res; 2015 Jan; 277():99-120. PubMed ID: 25036425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats.
    Willins DL; Meltzer HY
    J Pharmacol Exp Ther; 1997 Aug; 282(2):699-706. PubMed ID: 9262333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.